Cytokinetics (CYTK) Stock Overview
A late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
CYTK Community Fair Values
Create NarrativeSee what 12 others think this stock is worth. Follow their fair value or set your own to get alerts.
Cytokinetics, Incorporated Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$51.13 |
| 52 Week High | US$59.39 |
| 52 Week Low | US$29.31 |
| Beta | 0.62 |
| 1 Month Change | 32.22% |
| 3 Month Change | 51.36% |
| 1 Year Change | -8.50% |
| 3 Year Change | -4.16% |
| 5 Year Change | 134.49% |
| Change since IPO | -47.07% |
Recent News & Updates
Recent updates
Cytokinetics: Game-Changing Data Confirms Best-In-Class Potential
Sep 02
Precision Medicine And Late-stage Trials Will Expand Global Reach
Successful late-stage clinical trials, commercial readiness, and diversification in products position the company for strong growth and reduced dependence on a single therapy.The Cytokinetics, Incorporated (NASDAQ:CYTK) Analysts Have Been Trimming Their Sales Forecasts
May 20
Cytokinetics Nears Approval: 'Buy' The New Potential Cardiology Franchise With Aficamten
Mar 16These Analysts Think Cytokinetics, Incorporated's (NASDAQ:CYTK) Sales Are Under Threat
Mar 05Cytokinetics, Incorporated (NASDAQ:CYTK) Just Reported And Analysts Have Been Cutting Their Estimates
Mar 02Cytokinetics Aligns For U.S. Launch Amid HCM Market Evolution
Dec 31A Look At The Intrinsic Value Of Cytokinetics, Incorporated (NASDAQ:CYTK)
Dec 14Cytokinetics: On The Cusp Of Commercialization
Nov 14Cytokinetics: Aficamten Rolling NDA Submission Leads To Expansion Opportunities
Aug 13Cytokinetics' Aficamten: Heartfelt Potential Amid Market Woes
Jul 24Cytokinetics Decides To Go It Alone
May 24Cytokinetics, Incorporated: Buyout Speculation Persists
Apr 01Cytokinetics: CEO Talks Down Buyout Prospects
Mar 16Shareholder Returns
| CYTK | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -3.5% | -1.8% | 1.7% |
| 1Y | -8.5% | -9.7% | 18.7% |
Return vs Industry: CYTK exceeded the US Biotechs industry which returned -9.9% over the past year.
Return vs Market: CYTK underperformed the US Market which returned 18.5% over the past year.
Price Volatility
| CYTK volatility | |
|---|---|
| CYTK Average Weekly Movement | 13.0% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.2% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CYTK's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CYTK's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 498 | Robert Blum | www.cytokinetics.com |
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure.
Cytokinetics, Incorporated Fundamentals Summary
| CYTK fundamental statistics | |
|---|---|
| Market cap | US$6.12b |
| Earnings (TTM) | -US$606.31m |
| Revenue (TTM) | US$85.74m |
Is CYTK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CYTK income statement (TTM) | |
|---|---|
| Revenue | US$85.74m |
| Cost of Revenue | US$390.64m |
| Gross Profit | -US$304.90m |
| Other Expenses | US$301.41m |
| Earnings | -US$606.31m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.07 |
| Gross Margin | -355.62% |
| Net Profit Margin | -707.17% |
| Debt/Equity Ratio | -233.5% |
How did CYTK perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/14 21:12 |
| End of Day Share Price | 2025/09/12 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cytokinetics, Incorporated is covered by 41 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Huidong Wang | Barclays |
| Carter Gould | Barclays |
| Jason Zemansky | BofA Global Research |